Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 23

1.

Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer.

Ghadjar P, Oesch SL, Rentsch CA, Isaak B, Cihoric N, Manser P, Thalmann GN, Aebersold DM.

Radiat Oncol. 2014 May 28;9:122. doi: 10.1186/1748-717X-9-122.

PMID:
24885327
[PubMed - in process]
Free PMC Article
2.

Bacillus Calmette-Guérin Strain Differences Have an Impact on Clinical Outcome in Bladder Cancer Immunotherapy.

Rentsch CA, Birkhäuser FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C, Lagranderie M, Marchal G, Orgeur M, Bouchier C, Bachmann A, Ingersoll MA, Brosch R, Albert ML, Thalmann GN.

Eur Urol. 2014 Mar 12. pii: S0302-2838(14)00190-0. doi: 10.1016/j.eururo.2014.02.061. [Epub ahead of print]

PMID:
24674149
[PubMed - as supplied by publisher]
3.

Characterization and clinical relevance of ALDHbright populations in prostate cancer.

Le Magnen C, Bubendorf L, Rentsch CA, Mengus C, Gsponer J, Zellweger T, Rieken M, Thalmann GN, Cecchini MG, Germann M, Bachmann A, Wyler S, Heberer M, Spagnoli GC.

Clin Cancer Res. 2013 Oct 1;19(19):5361-71. doi: 10.1158/1078-0432.CCR-12-2857. Epub 2013 Aug 22.

PMID:
23969936
[PubMed - indexed for MEDLINE]
4.

Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease.

Zellweger T, Stürm S, Rey S, Zlobec I, Gsponer JR, Rentsch CA, Terracciano LM, Bachmann A, Bubendorf L, Ruiz C.

Endocr Relat Cancer. 2013 May 21;20(3):403-13. doi: 10.1530/ERC-12-0402. Print 2013 Jun.

PMID:
23580588
[PubMed - indexed for MEDLINE]
Free Article
5.

BCG-mediated bladder cancer immunotherapy: identifying determinants of treatment response using a calibrated mathematical model.

Rentsch CA, Biot C, Gsponer JR, Bachmann A, Albert ML, Breban R.

PLoS One. 2013;8(2):e56327. doi: 10.1371/journal.pone.0056327. Epub 2013 Feb 25.

PMID:
23451041
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Potential consequences of low biopsy core number in selection of patients with prostate cancer for current active surveillance protocols.

Müller G, Bonkat G, Rieken M, Wyler SF, Bubendorf L, Püschel H, Gasser TC, Bachmann A, Rentsch CA.

Urology. 2013 Apr;81(4):837-42. doi: 10.1016/j.urology.2012.10.068. Epub 2013 Feb 6.

PMID:
23395126
[PubMed - indexed for MEDLINE]
7.

Deep clonal profiling of formalin fixed paraffin embedded clinical samples.

Holley T, Lenkiewicz E, Evers L, Tembe W, Ruiz C, Gsponer JR, Rentsch CA, Bubendorf L, Stapleton M, Amorese D, Legendre C, Cunliffe HE, McCullough AE, Pockaj B, Craig D, Carpten J, Von Hoff D, Iacobuzio-Donahue C, Barrett MT.

PLoS One. 2012;7(11):e50586. doi: 10.1371/journal.pone.0050586. Epub 2012 Nov 30.

PMID:
23226320
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.

Biot C, Rentsch CA, Gsponer JR, Birkhäuser FD, Jusforgues-Saklani H, Lemaître F, Auriau C, Bachmann A, Bousso P, Demangel C, Peduto L, Thalmann GN, Albert ML.

Sci Transl Med. 2012 Jun 6;4(137):137ra72. doi: 10.1126/scitranslmed.3003586.

PMID:
22674550
[PubMed - indexed for MEDLINE]
Free Article
9.

Dismembered and non-dismembered retroperitoneoscopic pyeloplasty for the treatment of ureteropelvic junction obstruction in children.

Subotic S, Weiss H, Wyler S, Rentsch CA, Rassweiler J, Bachmann A, Teber D.

World J Urol. 2013 Jun;31(3):689-95. doi: 10.1007/s00345-012-0887-0. Epub 2012 May 22.

PMID:
22618575
[PubMed - indexed for MEDLINE]
10.

High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth.

Ruiz C, Oeggerli M, Germann M, Gluderer S, Stocker H, Andreozzi M, Thalmann GN, Cecchini MG, Zellweger T, Stürm S, Koivisto PA, Helin HJ, Gelmann EP, Glass AG, Gasser TC, Terracciano LM, Bachmann A, Wyler S, Bubendorf L, Rentsch CA.

Prostate. 2012 Nov;72(15):1678-87. doi: 10.1002/pros.22521. Epub 2012 Apr 2.

PMID:
22473923
[PubMed - indexed for MEDLINE]
11.

Urethral toxicity vs. cancer control--lessons to be learned from high-dose rate brachytherapy combined with intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer.

Ghadjar P, Rentsch CA, Isaak B, Behrensmeier F, Thalmann GN, Aebersold DM.

Brachytherapy. 2011 Jul-Aug;10(4):286-94. doi: 10.1016/j.brachy.2010.09.005. Epub 2010 Oct 28.

PMID:
21030318
[PubMed - indexed for MEDLINE]
12.

Improved detection of microbial ureteral stent colonisation by sonication.

Bonkat G, Rieken M, Rentsch CA, Wyler S, Feike A, Schäfer J, Gasser T, Trampuz A, Bachmann A, Widmer AF.

World J Urol. 2011 Feb;29(1):133-8. doi: 10.1007/s00345-010-0535-5. Epub 2010 Mar 21.

PMID:
20306317
[PubMed - indexed for MEDLINE]
13.

Madm (Mlf1 adapter molecule) cooperates with Bunched A to promote growth in Drosophila.

Gluderer S, Brunner E, Germann M, Jovaisaite V, Li C, Rentsch CA, Hafen E, Stocker H.

J Biol. 2010;9(1):9. doi: 10.1186/jbiol216. Epub 2010 Feb 11.

PMID:
20149264
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Prognostic significance of apoptotic cell death in bladder cancer: a tissue microarray study on 179 urothelial carcinomas from cystectomy specimens.

Karamitopoulou E, Rentsch CA, Markwalder R, Vallan C, Thalmann GN, Brunner T.

Pathology. 2010 Jan;42(1):37-42. doi: 10.3109/00313020903434397.

PMID:
20025478
[PubMed - indexed for MEDLINE]
15.

In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue.

Guzmán-Ramírez N, Völler M, Wetterwald A, Germann M, Cross NA, Rentsch CA, Schalken J, Thalmann GN, Cecchini MG.

Prostate. 2009 Nov 1;69(15):1683-93. doi: 10.1002/pros.21018.

PMID:
19644960
[PubMed - indexed for MEDLINE]
16.

Loss of inhibition over master pathways of bone mass regulation results in osteosclerotic bone metastases in prostate cancer.

Rentsch CA, Cecchini MG, Thalmann GN.

Swiss Med Wkly. 2009 Apr 18;139(15-16):220-5. doi: smw-12284. Review.

PMID:
19418305
[PubMed - indexed for MEDLINE]
Free Article
17.

Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer.

Ghadjar P, Matzinger O, Isaak B, Behrensmeier F, Stroux A, Rentsch CA, Thalmann GN, Aebersold DM.

Radiother Oncol. 2009 May;91(2):237-42. doi: 10.1016/j.radonc.2008.12.007. Epub 2009 Jan 21.

PMID:
19167121
[PubMed - indexed for MEDLINE]
18.

Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy.

Ghadjar P, Keller T, Rentsch CA, Isaak B, Behrensmeier F, Stroux A, Thalmann GN, Aebersold DM.

Brachytherapy. 2009 Jan-Mar;8(1):45-51. doi: 10.1016/j.brachy.2008.09.004. Epub 2008 Nov 26.

PMID:
19038584
[PubMed - indexed for MEDLINE]
19.

Editorial comment on: Expression of aquaporin 1 in primary renal tumors: a prognostic indicator of clear-cell renal cell carcinoma.

Rentsch CA, Bachmann A.

Eur Urol. 2009 Oct;56(4):699. doi: 10.1016/j.eururo.2008.10.015. Epub 2008 Oct 14. No abstract available.

PMID:
18930584
[PubMed - indexed for MEDLINE]
20.

BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo.

Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, Schwaninger R, Henriquez NV, Ten Dijke P, Borovecki F, Markwalder R, Thalmann GN, Papapoulos SE, Pelger RC, Vukicevic S, Cecchini MG, Löwik CW, van der Pluijm G.

Am J Pathol. 2007 Sep;171(3):1047-57.

PMID:
17724140
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk